| Treatment | Target | Summary results |
| Omalizumab | Anti-IgE | Reduced exacerbation rate Improved asthma score Reduced inhaled glucocortocisteroids and rescue medication |
| Mepolizumab | Anti-IL5 | Reduced exacerbation rate Reduced eosinophilia Improved symptom control and quality of life Reduced oral glucocorticosteroid dose |
| Reslizumab | Anti-IL5 | Reduced sputum eosinophils Improved pulmonary function Trend towards better asthma control |
| Golimumab | Anti-TNF-α | No improvement in pulmonary function No reduction in exacerbation rate Serious infection risks and malignancies |
| Etanercept | Anti-TNF-α | Inconsistent results Improvement in pulmonary function and quality of life versus no clinical benefit/misbalanced risk/benefit ratio |
| Daclizumab | Anti-IL2R chain | Improved asthma control and pulmonary function Reduction in SABA use Prolonged time to exacerbation |
| SCH527123 | Anti-CXCR2 | Small reduction in mild exacerbations Reduction in sputum neutrophils Trend toward improvement in asthma control |
| Lebrikizumab | Anti-IL13 | Improvement in pulmonary function |
| Tralokinumab | Anti-IL13 | Improvement in pulmonary function Reduction in β-agonist use No improvement in asthma control |
| AMG 317 | Anti-IL4R | No effect on asthma control or exacerbations |
IL: interleukin; TNF; tumour necrosis factor; IL2R: interleukin-2 receptor; SABA: short-acting β-agonist.